Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

Market Cap

298.81 Million GBp

Sector

Financial Services

Website

https://www.internationalbiotrust.com

Description

International Biotechnology Trust plc specializes in investments in development stage and late stage companies.

Read More

Overview

Value

23

Growth

2

Health

62

Management

35

Analyst Opinion

80

Total

40

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Has strong financial health
  • Price-to-earnings ratio of 5.2 is lower than the market average (19.6x)
  • Liked by analysts
  • Has strong dividend growth
  • Low preportion of income is paid as dividend

Risk Factors

  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Poor earnings and cashflow growth

Market Peers

IBT.L

Key Figures

PE Ratio (TTM)

5.25

Margin Of Safety (DCF)

-98.66%

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Buy

Share Buybacks

-2.27%

Dividend Yeild (TTM)

0.03%

Valuation

Value Score

23

  • Price-to-earnings ratio of 5.2 is lower than the market average (19.6x)
  • Estimated intrinsic-value of 9.96 GBp is lower than current price ( 733.00 GBp)
  • Free-cashflow-yeild of -0.03% is worse than the market average (4.7%)
  • Margin-of-safety of -98.66% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 0.1 GBp

Current Price: 740.5 GBp

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

5.25x

Free Cashflow Yeild

-0.03%

PE/Earnings Growth

N/A

Price/Book

10595.82x

Growth

Growth Score

2

  • Revenue growth has improved this yeara
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of -22.43% is lower than the market average (12.35%)

Revenue Growth

N/A

Earnings Growth

N/A

Cashflow Growth

-22.43%

Health

Health Score

62

  • Has a low level of debt
  • Assets cover liabilities
  • Cashflow is negative
  • High financial leverage and base interest rate exposure
  • Requires debt for normal operation to be sustainable
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

0.14x

Current Assets/Liabilities

11.15x

Free Cashflow/Total Debt

0.03x

Debt/Capital

3.00x

Dividend

Secure Dividend Score

48

  • At risk of being unsafe
  • Long term dividend payout ratio of -1.54% is considered good
  • Payout ratio (TTM) of 17.87% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Dividend yeild of 0.03% is less than the market average (1.85%)
  • Spending a higher percentage of their income on dividends than last 5 years

Dividend Yeild

0.03%

Dividend Growth

11.37%

Payout Ratio (Earnings)

17.87%

Payout Ratio (Cashflow)

-99.95%

Management

Management Score

35

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -6.63% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -782.99% is lower than the market average (15%)

Average Buybacks/Dilution

-2.27%

Recent Buybacks/Dilution

N/A

5 Year Price Volitility

11.84%

Return On Assets

-682.33%

Return On Capital Employed

-6.63%

Return On Equity

-782.99%

Return On Free Cashflow

15348.86%

Return On Investments

N/A

Analysts

Analyst Opinion

80

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

International Biotechnology Trust plc

Currency

GBp

Beta

0.286274

Vol Avg

43273

Ceo

Cik

Cusip

G4809R108

Exchange

London Stock Exchange

Full Time Employees

0

Industry

Asset Management

Sector

Financial Services

Ipo Date

1996-02-22

Address

10 Harewood Avenue

City

LONDON

State

Country

GB

Zip

WC2B 6ST

Phone

4402074217070

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies